Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.

D'Amico AV, Moul JW, Carroll PR, Cote K, Sun L, Lubeck D, Renshaw AA, Loffredo M, Chen MH. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. J Natl Cancer Inst. 2004 Apr 07; 96(7):509-15.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.